CN110198716A - 癌症治疗 - Google Patents

癌症治疗 Download PDF

Info

Publication number
CN110198716A
CN110198716A CN201880008126.XA CN201880008126A CN110198716A CN 110198716 A CN110198716 A CN 110198716A CN 201880008126 A CN201880008126 A CN 201880008126A CN 110198716 A CN110198716 A CN 110198716A
Authority
CN
China
Prior art keywords
erdatinib
treatment
serum phosphate
daily
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880008126.XA
Other languages
English (en)
Chinese (zh)
Inventor
K.斯托金斯
J.J.佩雷斯鲁舒
P.M.Z.德普尔
A.N.阿瓦汉尼
Y.洛里奥
A.O.斯夫克尔-拉特克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110198716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Publication of CN110198716A publication Critical patent/CN110198716A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
CN201880008126.XA 2017-02-06 2018-02-02 癌症治疗 Pending CN110198716A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
US62/455211 2017-02-06
EP17209098 2017-12-20
EP17209098.7 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
CN110198716A true CN110198716A (zh) 2019-09-03

Family

ID=61094531

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880008126.XA Pending CN110198716A (zh) 2017-02-06 2018-02-02 癌症治疗

Country Status (26)

Country Link
US (2) US11077106B2 (https=)
EP (2) EP4286005A3 (https=)
JP (3) JP2020505425A (https=)
KR (2) KR20250069693A (https=)
CN (1) CN110198716A (https=)
AU (2) AU2018216969B2 (https=)
BR (1) BR112019016043A2 (https=)
CA (1) CA3049737A1 (https=)
DK (1) DK3576740T3 (https=)
ES (1) ES2953005T3 (https=)
FI (1) FI3576740T3 (https=)
HR (1) HRP20230697T1 (https=)
HU (1) HUE062453T2 (https=)
IL (1) IL268463A (https=)
JO (1) JOP20190190B1 (https=)
LT (1) LT3576740T (https=)
MX (2) MX2019009304A (https=)
NZ (2) NZ755301A (https=)
PH (1) PH12019501885A1 (https=)
PL (1) PL3576740T3 (https=)
RS (1) RS64778B1 (https=)
SG (2) SG10202105110VA (https=)
SI (1) SI3576740T1 (https=)
SM (1) SMT202300233T1 (https=)
TW (1) TWI874925B (https=)
UA (1) UA126336C2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113645974A (zh) * 2019-03-29 2021-11-12 詹森药业有限公司 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
HUE062453T2 (hu) * 2017-02-06 2023-11-28 Janssen Pharmaceutica Nv Rákbetegség kezelése
EP3923942A1 (en) * 2019-02-12 2021-12-22 Janssen Pharmaceutica NV Cancer treatment
MA55486A (fr) * 2019-03-29 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial
CN115103678A (zh) * 2020-02-12 2022-09-23 詹森药业有限公司 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128411A1 (en) * 2015-02-10 2016-08-18 Astex Therapeutics Limited Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HUE062453T2 (hu) * 2017-02-06 2023-11-28 Janssen Pharmaceutica Nv Rákbetegség kezelése

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128411A1 (en) * 2015-02-10 2016-08-18 Astex Therapeutics Limited Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOSEP TABERNERO ET AL: "Phase I Dose-Escalation Study of JNJ-42756493，an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor，in Patients With Advanced Solid Tumors", 《JOURNAL OF CLINICAL ONCOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113645974A (zh) * 2019-03-29 2021-11-12 詹森药业有限公司 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
DK3576740T3 (da) 2023-07-24
TW202402290A (zh) 2024-01-16
JP2025024064A (ja) 2025-02-19
AU2024201871B2 (en) 2026-02-26
US20200022976A1 (en) 2020-01-23
NZ755301A (en) 2025-12-19
HRP20230697T1 (hr) 2023-10-13
SG11201907199QA (en) 2019-09-27
JP2023022190A (ja) 2023-02-14
ES2953005T3 (es) 2023-11-07
LT3576740T (lt) 2023-08-10
IL268463A (en) 2019-09-26
KR20250069693A (ko) 2025-05-19
EP4286005A3 (en) 2024-03-06
EP4286005A2 (en) 2023-12-06
MX2019009304A (es) 2019-09-19
JP7668777B2 (ja) 2025-04-25
SMT202300233T1 (it) 2023-09-06
US11077106B2 (en) 2021-08-03
TWI874925B (zh) 2025-03-01
US20220110935A1 (en) 2022-04-14
UA126336C2 (uk) 2022-09-21
CA3049737A1 (en) 2018-08-09
MX2022007955A (es) 2022-07-27
AU2018216969A1 (en) 2019-07-25
HUE062453T2 (hu) 2023-11-28
JOP20190190A1 (ar) 2019-08-04
KR20190110581A (ko) 2019-09-30
JP2020505425A (ja) 2020-02-20
BR112019016043A2 (pt) 2020-03-31
SG10202105110VA (en) 2021-06-29
RS64778B1 (sr) 2023-11-30
EP3576740B1 (en) 2023-06-14
EP3576740A1 (en) 2019-12-11
PL3576740T3 (pl) 2023-09-11
PH12019501885A1 (en) 2020-06-29
FI3576740T3 (fi) 2023-08-31
JOP20190190B1 (ar) 2024-04-18
NZ796822A (en) 2025-12-19
AU2018216969B2 (en) 2024-04-11
AU2024201871A1 (en) 2024-04-11
SI3576740T1 (sl) 2023-10-30

Similar Documents

Publication Publication Date Title
TWI798199B (zh) 癌症治療
JP7668777B2 (ja) 癌治療
CN113645975A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
JP2026016402A (ja) 癌治療
TW201726136A (zh) 一種ｅｇｆｒ／ｈｅｒ２受體酪氨酸激酶抑制劑在製備治療ｈｅｒ２突變癌症藥物中的用途
HK40103983A (en) Cancer treatment
HK40013982A (en) Cancer treatment
CN113645974A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
HK40018978A (en) Cancer treatment
HK40018978B (en) Cancer treatment
EA051616B1 (ru) Лечение рака
WO2022191870A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
EA052711B1 (ru) Лечение рака
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013982

Country of ref document: HK